Clinical Trials Logo

Hemodialysis Patients clinical trials

View clinical trials related to Hemodialysis Patients.

Filter by:

NCT ID: NCT00638300 Completed - Clinical trials for Hemodialysis Patients

Removal of Ligand-bound Iron During Intravenous (IV) Iron Administration in Hemodialysis (HD)

Start date: March 2008
Phase: N/A
Study type: Interventional

The study's hypothesis is that HD with large pore dialyzers remove to the dialysate iron which is bound to potentially dialyzable ligands, after it's release from intravenous iron compound administered during hemodialysis.

NCT ID: NCT00491868 Completed - Clinical trials for Hemodialysis Patients

Clinical Study of R744 to Hemodialysis Patients

Start date: June 2007
Phase: Phase 3
Study type: Interventional

This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of intravenous injections of R744 in renal anemia patients on Hemodialysis patients.

NCT ID: NCT00433888 Completed - Clinical trials for Hemodialysis Patients

Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients (Phase Ⅲ Study)

Start date: January 2007
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.

NCT ID: NCT00433693 Completed - Clinical trials for Hemodialysis Patients

Correction Study of R744 in Renal Anemia Patients on Hemodialysis

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.

NCT ID: NCT00431249 Completed - Clinical trials for Peripheral Vascular Disease

Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease

Start date: February 2007
Phase: Phase 4
Study type: Interventional

Peripheral arterial disease (PAD) is the most common manifestation of systemic atherosclerosis and accounts for significant morbidity and mortality among end-stage renal disease (ESRD) patients. However, few studies have identified the prevalence and clinical impact of PAD in this specific population. Objectives: To perform a single-blinded parallel, controlled trial to examine the effect of cilostazol treatment on plasma VEGF levels, tissue factors , inflammatory markers (such as IL-6, hsCRP) levels, oxidative stress markers in ESRD patients with PAD Material and methods Fourty HD patients on maintenance HD for > 3months were enrolled in this prospective, single-blinded, randomized study. These patients were randomly allocated into 2 arms. After baseline assessment, patients in the treatment arm received 12 weeks of added on therapy with cilostazol 100mg/day. Blood pressure, heart rate, oxidative stress (malonyldialdehyde, protein carbonyl and ADMA), inflammatory markers (hsCRP, IL-6) and plasma, VEGF and tissue factors levels were measured before and after treatment.

NCT ID: NCT00259714 Terminated - Hypertension Clinical Trials

Dialysate Sodium Individualization in Hemodialysis

Start date: March 2006
Phase: Phase 1
Study type: Interventional

Salt and water excess is an essential mechanism of hypertension. This is particularly relevant to patients with end stage kidney disease (ESKD) on dialysis. We have demonstrated that individualization of the sodium concentration in the dialysate as to match the patient's own serum sodium concentration leads to less thirst, interdialytic weight gain, and better BP control in hypertensive patients. In this study we will evaluate the mechanisms underlying this response by measuring systemic hemodynamics, body volume spaces, and biochemical marker of volume status.